LDK378

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Normal Hepatic Function

Conditions

Normal Hepatic Function, Impaired Hepatic Function

Trial Timeline

Jan 1, 2014 → Sep 1, 2016

NCT ID

NCT01950481

About LDK378

LDK378 is a phase 1 stage product being developed by Novartis for Normal Hepatic Function. The current trial status is completed. This product is registered under clinical trial identifier NCT01950481. Target conditions include Normal Hepatic Function, Impaired Hepatic Function.

What happened to similar drugs?

4 of 6 similar drugs in Normal Hepatic Function were approved

Approved (4) Terminated (2) Active (2)

✅DonepezilEisaiApproved

✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved

✅cyclosporine micro-emulsionNovartisApproved

✅Aspirin 100 mg + PlaceboBayerApproved

🔄Gadopentetate dimeglumine (Magnevist)BayerPhase 3

🔄lixivaptan + placeboBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01947608	Pre-clinical	Completed	—	—	Non-small Cell Lung Cancer (NSCLC)
NCT02450903	Phase 2	Completed	Aug 21, 2015	May 24, 2018	Non-Small-Cell Lung Cancer
NCT02040870	Phase 1/2	Completed	Mar 7, 2014	Jul 27, 2017	Non-Small Cell Lung Cancer
NCT01950481	Phase 1	Completed	Jan 1, 2014	Sep 1, 2016	Normal Hepatic Function
NCT01685138	Phase 2	Completed	Dec 20, 2012	Jan 22, 2018	Non-Small Cell Lung Cancer
NCT01685060	Phase 2	Completed	Nov 26, 2012	Mar 29, 2016	Non-Small Cell Lung Cancer
NCT01634763	Phase 1	Completed	Jun 1, 2012	Jan 1, 2016	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
NCT01283516	Phase 1	Completed	Jan 24, 2011	May 3, 2016	Tumors Characterized by Genetic Abnormalities of ALK

Competing Products

20 competing products in Normal Hepatic Function

See all competitors

Product	Company	Stage	Hype Score
Roxadustat	Astellas Pharma	Phase 1	29
Donepezil	Eisai	Approved	43
eribulin mesylate	Eisai	Phase 2	35
Lurasidone HCl	Sumitomo Pharma	Phase 1	29
Eybelis ophthalmic solution 0.002%	Santen Pharmaceutical	Approved	39
Triptorelin	Merck	Pre-clinical	26
Temozolomide + Vorinostat	Merck	Phase 2	35
LDE225	Novartis	Phase 1	29
LDK378	Novartis	Phase 1	29
cyclosporine micro-emulsion	Novartis	Approved	35
LEE011	Novartis	Phase 1	29
LEE011	Novartis	Phase 1	29
mycophenolate mofetil	Roche	Phase 1	29
filgrastim	Amgen	Pre-clinical	26
PF-06423264	Pfizer	Phase 1	21
PF-05221304	Pfizer	Phase 1	29
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution	Bristol Myers Squibb	Phase 1	29
tolebrutinib	Sanofi	Phase 1	29
Venglustat (GZ402671)	Sanofi	Phase 1	29
Rilzabrutinib	Sanofi	Phase 1	29